Outlook Therapeutics, Inc.
OTLK
$0.50
-$0.01-1.37%
NASDAQ
| 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -14.60% | 43.93% | 62.26% | 62.26% | 9.06% |
| Gross Profit | 19.60% | -36.65% | -62.26% | -62.26% | -9.06% |
| SG&A Expenses | 33.39% | 47.47% | 49.91% | 35.48% | 12.25% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -4.50% | 20.96% | 27.69% | 73.75% | 34.97% |
| Operating Income | 6.47% | -18.50% | -27.69% | -73.75% | -34.97% |
| Income Before Tax | 15.11% | 53.81% | 113.27% | 9.10% | -27.78% |
| Income Tax Expenses | -55,521.43% | 0.00% | 0.00% | 0.00% | 0.00% |
| Earnings from Continuing Operations | 17.17% | 53.81% | 113.27% | 9.10% | -27.78% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 17.17% | 53.81% | 113.27% | 9.10% | -27.78% |
| EBIT | 6.47% | -18.50% | -27.69% | -73.75% | -34.97% |
| EBITDA | 6.49% | -18.50% | -27.66% | -73.74% | -34.87% |
| EPS Basic | 76.01% | 86.30% | 111.92% | -28.94% | -40.84% |
| Normalized Basic EPS | 47.08% | 76.63% | 115.90% | 63.62% | 35.16% |
| EPS Diluted | 83.00% | 89.82% | 87.55% | -99.04% | -99.51% |
| Normalized Diluted EPS | 49.55% | 77.41% | 113.91% | 59.75% | 31.99% |
| Average Basic Shares Outstanding | 87.58% | 82.31% | 92.10% | 65.32% | 48.32% |
| Average Diluted Shares Outstanding | 82.07% | 76.07% | 96.33% | 69.67% | 52.82% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |